Clinical Trial Update: Open-label Study of TAK-875 [Phase 3]

View source ↗

Summary

Open-label Phase 3 study of fasiglifam (TAK-875) for diabetes mellitus has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• TAK-875 (fasiglifam) (fasiglifam)

Snippet

Sponsor: Takeda | Conditions: Diabetes Mellitus | Phase 3 | Status: COMPLETED